U.S. markets closed
  • S&P 500

    3,811.15
    -18.19 (-0.48%)
     
  • Dow 30

    30,932.37
    -469.63 (-1.50%)
     
  • Nasdaq

    13,192.35
    +72.95 (+0.56%)
     
  • Russell 2000

    2,201.05
    +0.88 (+0.04%)
     
  • Crude Oil

    61.66
    +0.16 (+0.26%)
     
  • Gold

    1,733.00
    +4.20 (+0.24%)
     
  • Silver

    26.70
    +0.26 (+0.98%)
     
  • EUR/USD

    1.2076
    -0.0110 (-0.91%)
     
  • 10-Yr Bond

    1.4600
    -0.0580 (-3.82%)
     
  • GBP/USD

    1.3944
    -0.0069 (-0.49%)
     
  • USD/JPY

    106.5500
    +0.3200 (+0.30%)
     
  • BTC-USD

    44,342.18
    -2,957.23 (-6.25%)
     
  • CMC Crypto 200

    912.88
    -20.25 (-2.17%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    28,966.01
    -1,202.29 (-3.99%)
     

Why Johnson & Johnson Inspires Cramer's Bullishness On Disney, Visa, Mastercard

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Jayson Derrick
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

During a Wednesday conference call, Johnson & Johnson (NYSE: JNJ) executives inadvertently made the case for buying Walt Disney Co (NYSE: DIS), Visa Inc (NYSE: V) and Mastercard Inc (NYSE: MA), according to CNBC's Jim Cramer.

Cramer Sees 'Something Compelling' From Johnson & Johnson

Johnson & Johnson's post-earnings conference call focused in part on its ongoing efforts to develop a coronavirus vaccine, Cramer said on his "Mad Money" show.

Management displayed a confident tone and suggested it has "something compelling up their sleeves," the CNBC host said. 

The call was so compelling that investors should have left wishing they owned stocks with exposure to travel or leisure, such as Disney, Visa, and Mastercard, he said. 

Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.

Cramer Says 'Toxic' Stocks Might Be A Buy

Johnson & Johnson is "experienced" at producing vaccines and "way ahead" of its rivals, Cramer said.

A vaccine is the one and only way to "beat this disease for good," as it not only prevents people from getting sick, but prevents people from being a carrier, he said. 

When this happens, investors will likely look back at this point in time and "wish" they owned stocks that are now considered to be "toxic," Cramer said.

What's Next For Johnson & Johnson 

Johnson & Johnson said it can manufacture between 600 million and 900 million vaccines in 2021 if ongoing trials prove to be successful.  

Human testing is expected to commence in September, followed by an emergency use authorization for public consumption.

Johnson & Johnson shares were up 0.11% at $147.82 at the time of publication Thursday.

Related Links:

3 Frontrunners In COVID-19 Vaccine Development: What You Need To Know

Sanofi CEO Talks Coronavirus Vaccine Development, Potential Treatment

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.